             
|
Paper 3 (0845)
CHEMOEMBOLISATION (CE) FOR HEPATIC METASTASES IN MEDULLARY THYROID CARCINOMA (MTC)
Background: Hepatic metastases in MTC may cause hypercalcitonemia-associated diarrhoea, pain and impair liver function. Currently no curative treatment for systemic disease in MTC exists. Symptom palliation, biochemical and survival effect were evaluated.
The 26th Annual Meeting of the American
Association of Endocrine Surgeons
April 3rd- 5th,2005 - Paradisus Riviera Cancun.
Kerstin Lorenz MD, Curd Behrmann MD; Carsten Sekulla PhD,
Henning Dralle MD
Martin-Luther University Halle-Wittenberg, Germany
Methods: From 1997 -2004 10 MTC patients with hepatic metastasing sporadic or hereditary MTC received angiographic liver-CE with epirubicine. Five to nine courses in monthly interval were applied. Tumor markers, liver-CT and patient`s symptom-questionnaire were analyzed for outcome.
Results: There was remission of hepatic lesions in size and number in 4, partial remission in 3, in 2 no change and progression in 1 after nine months respectively. Calcitonin and CEA decreased postinterventionally but showed slow progression in long-term follow-up. Symptom control of severe diarrhoea and pain was successful in eight. Patient`s satisfaction was excellent; except for one all would repeat or continue CE when indicated. There was no complication in this series. CE did not affect liver function. Long-term follow-up found 7 patients alive with tumor at 13 to 71 months, three patients died from tumor 31-65 months after CE.
Conslusions: With CE long-term stabilization or at least transient remission of hepatic metastases in MTC is achieved for the majority in this study. Although small in number, CE provided excellent palliation in regard to symptoms of hepatic metastases and patient`s acceptance was very good. Improvement of Results: can be expected with further development of chemotherapeutics.